What is Pheast?
Founded in 2020 and headquartered in Palo Alto, California, Pheast Therapeutics is a cancer immunotherapy company focused on developing novel checkpoint therapies. The company's core mission is to harness the innate immune system to combat cancer, positioning itself at the forefront of innovative oncology treatments. This strategic financing indicates a strong market belief in Pheast's approach to developing next-generation cancer therapies.
How much funding has Pheast raised?
Pheast has raised a total of $76M across 1 funding round:
Series A
$76M
Series A (2022): $76M with participation from Risk and Return, Alexandria Venture Investments, ARCH Venture Partners, and Catalio Capital Management
Key Investors in Pheast
Risk and Return
RSquared VC is a venture capital firm focused on investing in companies that enhance national resilience and address various risks. The firm aims to support innovative solutions that contribute to the stability and security of communities.
ARCH Venture Partners
ARCH Venture Partners is a leading early-stage venture capital firm that creates and invests in life sciences and advanced technology companies, often co-founding startups with scientists and entrepreneurs to commercialize innovations from universities, corporate R&D groups, and national laboratories.
Catalio Capital Management
Catalio Capital Management is a New York-based investment firm specializing in innovative healthcare investing across private, public, and credit markets. Founded by George Petrocheilos and Dr. Jacob Vogelstein, the firm focuses on breakthrough biomedical technology companies.
What's next for Pheast?
The substantial enterprise-level funding Pheast Therapeutics has garnered suggests a pivotal growth phase. This capital infusion is likely earmarked for accelerating its research and development pipeline, expanding its clinical trial capabilities, and potentially scaling its operational infrastructure. The company's focus on novel checkpoint therapies indicates a strategic move to address unmet needs in cancer treatment, aiming to solidify its position as a key player in the biopharmaceutical sector.
See full Pheast company page
